Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD8 enriched young autologous tumor-infiltrating lymphocytes

A preparation of autologous young tumor infiltrating lymphocytes (TILs), that are isolated from the patient's tumor tissue that are CD8 enriched and expanded ex vivo, with potential antineoplastic and immunomodulating activities. Upon administration of the CD8 enriched young autologous TILs, the TILs re-infiltrate the tumor, recognize the tumor cells and initiate tumor cell lysis. This inhibits tumor cell growth.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	CD8 enriched young autologous TILs

CD8 enriched young autologous tumor-infiltrating lymphocytes

Search NCI's Drug Dictionary